#USA #Prague #Kedrion Biopharma #IPIC 2025 #Secondary Immunodeficiencies

Kedrion Biopharma Takes Center Stage at IPIC 2025

Kedrion Biopharma, a leading biopharmaceutical company specialized in plasma-derived therapies, recently announced its participation in the International Primary Immunodeficiencies Congress (IPIC) 2025 held in Prague from November 5 to November 7. This significant event brings together experts and stakeholders in the field of immunology to discuss advancements and challenges.

Highlighting Secondary Immunodeficiencies

Kedrion's engagement at IPIC 2025 includes hosting a satellite symposium focused on a pressing concern in immunology: secondary immunodeficiencies (SIDs) associated with hematological malignancies. The symposium is led by Dr. Fabian Peissker, with contributions from renowned experts. Professor Hermann Wolf from Sigmund Freud University in Vienna and Dr. Federica Pulvirenti from Policlinico Umberto I in Rome will share their insights on the complexities surrounding the diagnosis and treatment of secondary immunodeficiencies.

SIDs pose a significant clinical challenge, particularly in patients suffering from hematological B-cell tumors, due to their intricate pathogenesis and increased risk of life-threatening infections. While advancements in cancer therapies have improved survival rates, complications such as hypogammaglobulinemia and subsequent infections continue to impact treatment outcomes and patients' quality of life. Early diagnosis and appropriate treatment, including immunoglobulin replacement therapy, are crucial to enhancing patient care and reducing infection-related complications.

Commitment to Collaboration and Research

Kedrion's participation in IPIC 2025 underscores the company's dedication to advancing knowledge and fostering collaboration within the medical and scientific communities, particularly concerning secondary immunodeficiencies. By sponsoring the symposium, Kedrion showcases its growing commitment to this evolving domain.

In addition to the symposium, Kedrion features prominently with a booth, three scientific poster sessions, and active participation from international delegates. These platforms aim to present the latest scientific information and share the impact of ongoing research in immunodeficiency treatments. The 'Medical Information Corner' at Kedrion's booth serves as a valuable resource for conference attendees, providing direct access to scientific and medical experts.

Roberto Crea, Head of the Immunology Therapeutics Unit at Kedrion, emphasizes the necessity of ongoing research to better understand the interplay between primary and secondary immunodeficiencies. He stresses that it is only through collaboration across various healthcare disciplines—particularly between specialists treating primary and secondary conditions—that meaningful advancements in patient care can be made.

Expert Insights and Collaborative Approaches

Martine Pergent, President of the International Patient Organisation for Primary Immunodeficiencies (IPOPI), highlights the importance of leveraging expertise from all facets of immunodeficiencies to meet the needs of SID patients. She notes that primary immunodeficiencies (PIDs) are no longer solely characterized by infections but encompass a wider range of overlapping conditions. Thus, addressing secondary immunodeficiencies is critical, drawing upon the extensive experience in managing chronic diseases and infection prevention found in the realm of PIDs.

The Future of Immunodeficiency Research

The IPIC serves as a premier international congress addressing primary immunodeficiencies and congenital immune system disorders, focusing on patient-centered approaches. The 2025 edition expects over 900 participants from more than 70 countries, creating a unique platform for scientific discussion and collaboration. Kedrion recognizes this gathering as an opportunity to deepen its engagement, and the sponsored symposium will explore the latest developments regarding SIDs, inviting all participants to partake in this vital dialogue.

As the congress unfolds, attendees can access scientific insights at Kedrion’s stand (No. 17), where discussions about advancements in managing immunodeficiencies will take place, alongside opportunities to connect with leaders in the field.

For more information about Kedrion and its initiatives, visit Kedrion’s website.